Ask AI

CAR-T Conversations in RRMM: Hot Topics in Bridging, Sequencing, and Cross-Setting Care

Start Activity
Video
Video Start Activity
This activity is available for 1.00 CME/CE credit(s).

Released: November 13, 2026

Expiration: May 12, 2027

See Activity Collection

Step 1 of 5

1 Pre Assessment 2 Video 3 Post Assessment 4 Evaluation 5 Credit

In this on-demand webcast, experts discuss optimization of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma, with a focus on patient selection, treatment timing, bridging strategies, sequencing, and toxicity management. Drawing on phase III clinical trial findings from KarMMa-3 and CARTITUDE-4, subgroup analyses, and real-world evidence, the experts examine the efficacy and safety of idecabtagene vicleucel and ciltacabtagene autoleucel, including outcomes in older patients and those with high-risk disease or renal impairment. Case-based discussions address early referral, selection of holding and bridging therapies, the role of talquetamab before BCMA-directed CAR T-cell therapy, and sequencing considerations involving bispecific antibodies. The experts also review strategies for recognizing and managing acute and delayed toxicities, including cytokine release syndrome, neurotoxicity, infections, and immune effector cell-associated enterocolitis, emphasizing multidisciplinary care coordination to improve treatment access, safety, and patient outcomes.

Doris K. Hansen
Doris K. Hansen, MD
Surbhi Sidana
Surbhi Sidana, MD
CAR T in RRMM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
Begin Your Video
1.

How many people with multiple myeloma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

Do you work at an institution with a CAR T-cell therapy program?

4.

Which decision point is most challenging in your practice?

5.

Patient Case 1: 36-Yr-Old Woman With MM



  • 36-yr-old woman was diagnosed with kappa FLC MM in 2024​

    • ISS stage III

    • Cytogenetics/FISH: presence of del(17p); t(4:14) and 1q amplification​



  • She started DVRD as first-line therapy and underwent ASCT in February 2025 → bortezomib + lenalidomide as maintenance therapy​

  • However, she experienced symptomatic disease progression in September 2025​

Based on current indications, which CAR T-cell therapy would this patient be eligible for, if any?

6.

A 62-yr-old patient with relapsed/refractory MM is referred for BCMA-directed CAR T-cell therapy after 4 prior lines of therapy. The patient is penta-drug refractory (including to a proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody) and has a high disease burden with rapidly progressive symptoms. Manufacturing is expected to take approximately 4-5 wk.​

Which of the following would be the most appropriate choice for bridging therapy for this patient?

7.

Which combination of findings is most characteristic of delayed parkinsonian-like neurotoxicity reported after CAR T-cell therapy?

Begin Your Video